Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) have been assigned an average rating of “Buy” from the twenty-six brokerages that are currently covering the firm, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell rating, eight have given a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $109.22.
BMRN has been the topic of several recent analyst reports. Goldman Sachs Group reiterated a “buy” rating and set a $129.00 target price on shares of BioMarin Pharmaceutical in a research report on Friday, October 6th. JPMorgan Chase & Co. set a $130.00 target price on BioMarin Pharmaceutical and gave the stock a “buy” rating in a research report on Sunday, October 29th. Stifel Nicolaus reduced their target price on BioMarin Pharmaceutical from $107.00 to $105.00 and set a “buy” rating on the stock in a research report on Friday, October 27th. BMO Capital Markets reiterated a “buy” rating and set a $117.00 target price on shares of BioMarin Pharmaceutical in a research report on Friday, October 20th. Finally, SunTrust Banks set a $115.00 target price on BioMarin Pharmaceutical and gave the stock a “buy” rating in a research report on Thursday, October 19th.
In related news, CEO Jean Jacques Bienaime sold 10,000 shares of the firm’s stock in a transaction dated Friday, January 5th. The stock was sold at an average price of $90.32, for a total transaction of $903,200.00. Following the sale, the chief executive officer now directly owns 235,894 shares in the company, valued at approximately $21,305,946.08. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Henry J. Fuchs sold 15,000 shares of the firm’s stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $89.23, for a total value of $1,338,450.00. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 60,750 shares of company stock worth $5,439,788. Company insiders own 1.85% of the company’s stock.
BioMarin Pharmaceutical (BMRN) traded up $1.04 during midday trading on Friday, reaching $91.60. The company had a trading volume of 822,492 shares, compared to its average volume of 1,250,000. BioMarin Pharmaceutical has a 1 year low of $80.10 and a 1 year high of $100.51. The stock has a market capitalization of $16,270.00, a P/E ratio of -110.36 and a beta of 1.81. The company has a debt-to-equity ratio of 0.41, a current ratio of 4.91 and a quick ratio of 3.81.
BioMarin Pharmaceutical (NASDAQ:BMRN) last released its earnings results on Thursday, October 26th. The biotechnology company reported ($0.07) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.13) by $0.06. BioMarin Pharmaceutical had a negative return on equity of 4.60% and a negative net margin of 12.45%. The firm had revenue of $334.18 million for the quarter, compared to the consensus estimate of $347.38 million. During the same period in the prior year, the business posted $0.02 earnings per share. The firm’s revenue for the quarter was up 19.4% compared to the same quarter last year. sell-side analysts predict that BioMarin Pharmaceutical will post -0.63 EPS for the current fiscal year.
WARNING: This piece of content was reported by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this piece of content on another domain, it was copied illegally and reposted in violation of US and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://stocknewstimes.com/2018/02/11/biomarin-pharmaceutical-inc-bmrn-receives-109-32-average-target-price-from-brokerages.html.
BioMarin Pharmaceutical Company Profile
BioMarin Pharmaceutical Inc is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company’s therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A).
Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.